TMCnet News
Araris Biotech AG to Present at 12th Annual World ADC Digital ConferenceZURICH, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, announced that data from its linker technology are being presented at the 12th annual World ADC San Diego Conference - The Digital Edition. The presentation, entitled "Broadening the therapeutic index of antibody-drug conjugates using Araris peptide linkers for site-specific bioconjugation,” will be shown on Wednesday, October 13, 2021 at 3:30-4:30 p.m. EDT. Presentation highlights:
"Our proprietary linker technology and assembly method enables us to develop ADCs that are generated in one-step from native or engineered ‘off-the-shelf’ antibodies, so no re-engineering of the antibody is needed for payload conjugation,” said Philipp Spycher, Ph.D., Chief Executive Officer at Araris BiotechAG. “The resulting ADCs have favorable biophysical properties with well-defined drug-to-antibody ratio. We’re excited to share how our technology has the potential to generate ADCs that efficiently and safely deliver high amounts of payloads to tumors and have the potential to make a meaningful difference for patients living with cancer.” Additionally, Araris has been shortlisted as part of the top 5 companies in the category for “Best ADC Platform Technology” in the World ADC awards. For more information, please visit www.ararisbiotech.com or follow Araris on Twitter and LinkedIn. Corporate Contact: Media Contact: |